Changes in regulations such as a relaxation in regulatory requirements or the introduction of simplified approval procedures, or an increase in regulatory requirements that DD has difficulty satisfying or that make its services less competitive, could eliminate or substantially reduce the demand for its services.Since 2018, the Company has invested net cash of approximately $2.9 billion in strategic business acquisitions.Other MCOs adopt broader networks with generally uniform fee structures for participating clinical laboratories.Capitation shifts the risk of increased test utilization (and the underlying mix of testing services) to the commercial laboratory provider.The 36 IndexCompany makes significant efforts to obtain adequate compensation for its services in its capitated arrangements.Pursuant to legislation passed in late 2003, the percentage of Medicare beneficiaries enrolled in Managed Medicare plans has increased.Additionally, few barriers to entering the CRO industry further increases possible new competition.Despite these safeguards, the Company cannot guarantee protection from corrupt acts committed by employees or third parties associated with the Company.There is competition among CROs for both customers and potential acquisition candidates.To maintain and grow its business, the Company needs to obtain and retain new customers and business partners.The Company depends on third parties to provide supplies and services critical to the Company’ s business.The Company receives and stores certain personal and financial information about its customers.In these cases, revenue is recognized when services are rendered or delivered.The planned spin-off will result in two independent companies, each poised for strong, sustainable growth.DDA majority of DD’ s revenues are earned under contracts that are long term in nature, ranging in duration from a few months to many years.On January 9, 2023, Thomas (Tom) Pike joined the Company as president and chief executive officer of its DD Clinical Development business unit, and when the planned spin-off is complete, Mr. Pike will become the chief executive officer and chairman of the board of directors of the independent, publicly listed company.PatientsThis portfolio includes revenue from uninsured patients and member cost-share for insured patients (e. g., coinsurance, deductibles and non-covered services).Dx bills insured patients as directed by their health plan and after consideration of the fees and terms associated with an established health plan contract.Third-party reimbursement is also received through capitation agreements with MCOs and independent physician associations (IPAs).For the early development reporting unit, which is part of the DD segment, the fair value of the business exceeded the book value by approximately 10%.Spin-Off of the Company's CDCS BusinessOn July 28, 2022, the Company announced that the Board authorized the Company to pursue a spin-off of the Company’ s wholly owned CDCS business to its shareholders through a tax-free transaction.On February 9, 2023, the Company announced that the name of the CDCS business will become Fortrea in connection with the planned spin-off.COVID-19 OutlookWhile the Company anticipates that COVID-19 will continue impacting its business in 2023 and potentially beyond, the Company expects a continued decline in demand for COVID-19 Testing, with the potential for increases in demand at different times and across different geographies.Revenue RecognitionDxWithin the Dx segment, a revenue transaction is initiated when Dx receives a requisition order to perform a diagnostic test.These suits typically allege that the Company has made false statements and/or certifications in connection with claims for payment from U. S. federal or state healthcare programs.